OBJECTIVE: CX(3) CR1 is a chemokine receptor that uniquely binds to its ligand fractalkine (CX(3) CL1) and has been shown to be important in inflammatory arthritis responses, largely due to its effects on cellular migration. This study was undertaken to test the hypothesis that genetic deficiency of CX(3) CR1 is protective in the chronic inflammatory arthritis model collagen-induced arthritis (CIA). Because CX(3) CR1 is expressed on T cells and antigen-presenting cells, we also examined adaptive immune functions in this model. METHODS: Autoantibody formation, clinical, histologic, T cell proliferative, and cytokine responses were evaluated in wild-type and CX(3) CR1-deficient DBA/1J mice after immunization with heterologous type II collagen (CII). RESULTS: CX(3) CR1(-/-) mice had an ∼30% reduction in arthritis severity compared to wild-type mice, as determined by 2 independent measures, paw swelling (P < 0.01) and clinical disease score (P < 0.0001). Additionally, compared to wild-type mice, CX(3) CR1(-/-) mice had an ∼50% decrease in anti-CII autoantibody formation (P < 0.05), decreased Th17 intraarticular cytokine expression (P < 0.01 for interleukin-17 [IL-17] and P < 0.001 for IL-23), and decreased total numbers of Th17 cells in inflamed joints (P < 0.05). CONCLUSION: Our findings indicate that CX(3) CR1 deficiency is protective in inflammatory arthritis and may have effects that extend beyond migration that involve adaptive immune responses in autoimmune disease.
OBJECTIVE:CX(3) CR1 is a chemokine receptor that uniquely binds to its ligand fractalkine (CX(3) CL1) and has been shown to be important in inflammatory arthritis responses, largely due to its effects on cellular migration. This study was undertaken to test the hypothesis that genetic deficiency of CX(3) CR1 is protective in the chronic inflammatory arthritis model collagen-induced arthritis (CIA). Because CX(3) CR1 is expressed on T cells and antigen-presenting cells, we also examined adaptive immune functions in this model. METHODS: Autoantibody formation, clinical, histologic, T cell proliferative, and cytokine responses were evaluated in wild-type and CX(3) CR1-deficient DBA/1J mice after immunization with heterologous type II collagen (CII). RESULTS:CX(3) CR1(-/-) mice had an ∼30% reduction in arthritis severity compared to wild-type mice, as determined by 2 independent measures, paw swelling (P < 0.01) and clinical disease score (P < 0.0001). Additionally, compared to wild-type mice, CX(3) CR1(-/-) mice had an ∼50% decrease in anti-CII autoantibody formation (P < 0.05), decreased Th17 intraarticular cytokine expression (P < 0.01 for interleukin-17 [IL-17] and P < 0.001 for IL-23), and decreased total numbers of Th17 cells in inflamed joints (P < 0.05). CONCLUSION: Our findings indicate that CX(3) CR1 deficiency is protective in inflammatory arthritis and may have effects that extend beyond migration that involve adaptive immune responses in autoimmune disease.
Authors: Liat Bar-On; Tal Birnberg; Kanako L Lewis; Brian T Edelson; Dunja Bruder; Kai Hildner; Jan Buer; Kenneth M Murphy; Boris Reizis; Steffen Jung Journal: Proc Natl Acad Sci U S A Date: 2010-08-02 Impact factor: 11.205
Authors: T Imai; K Hieshima; C Haskell; M Baba; M Nagira; M Nishimura; M Kakizaki; S Takagi; H Nomiyama; T J Schall; O Yoshie Journal: Cell Date: 1997-11-14 Impact factor: 41.582
Authors: Jasper J Haringman; Danielle M Gerlag; Tom J M Smeets; Dominique Baeten; Filip van den Bosch; Barry Bresnihan; Ferdinand C Breedveld; Huib J Dinant; Francois Legay; Hermann Gram; Pius Loetscher; Robert Schmouder; Thasia Woodworth; Paul P Tak Journal: Arthritis Rheum Date: 2006-08
Authors: Hendrik Poeck; Moritz Wagner; Julia Battiany; Simon Rothenfusser; Daniela Wellisch; Veit Hornung; Bernd Jahrsdorfer; Thomas Giese; Stefan Endres; Gunther Hartmann Journal: Blood Date: 2003-12-30 Impact factor: 22.113
Authors: David H McDermott; Alan M Fong; Qiong Yang; Joan M Sechler; L Adrienne Cupples; Maya N Merrell; Peter W F Wilson; Ralph B D'Agostino; Christopher J O'Donnell; Dhavalkumar D Patel; Philip M Murphy Journal: J Clin Invest Date: 2003-04 Impact factor: 14.808
Authors: Emilia M Zywot; Natalia Orlova; Song Ding; Rishi R Rampersad; Emily M Rabjohns; Victoria A Wickenheisser; Qunzhao Wang; Joshua G Welfare; Lauren Haar; Amanda M Eudy; Teresa K Tarrant; David S Lawrence Journal: Adv Ther (Weinh) Date: 2021-10-13
Authors: John S Lewis; Bridgette D Furman; Evan Zeitler; Janet L Huebner; Virginia B Kraus; Farshid Guilak; Steven A Olson Journal: Arthritis Rheum Date: 2013-03
Authors: Patrick M Giguère; Matthew J Billard; Geneviève Laroche; Brian K Buckley; Roman G Timoshchenko; Marcus W McGinnis; Denise Esserman; Oded Foreman; Peng Liu; David P Siderovski; Teresa K Tarrant Journal: Mol Immunol Date: 2012-12-29 Impact factor: 4.407
Authors: Teresa K Tarrant; Matthew J Billard; Roman G Timoshchenko; Marcus W McGinnis; D Stephen Serafin; Oded Foreman; Denise A Esserman; Nelson J Chao; William E Lento; David M Lee; Dhavalkumar Patel; David P Siderovski Journal: J Leukoc Biol Date: 2013-08-09 Impact factor: 4.962
Authors: Lei Dong; Johannes Nordlohne; Shuwang Ge; Barbara Hertel; Anette Melk; Song Rong; Hermann Haller; Sibylle von Vietinghoff Journal: J Am Soc Nephrol Date: 2015-10-08 Impact factor: 10.121
Authors: Timothy J Break; Martin Jaeger; Norma V Solis; Scott G Filler; Carlos A Rodriguez; Jean K Lim; Chyi-Chia Richard Lee; Jack D Sobel; Mihai G Netea; Michail S Lionakis Journal: Infect Immun Date: 2014-12-29 Impact factor: 3.441